MX2022002473A - Variantes de lipasa modificadas geneticamente. - Google Patents

Variantes de lipasa modificadas geneticamente.

Info

Publication number
MX2022002473A
MX2022002473A MX2022002473A MX2022002473A MX2022002473A MX 2022002473 A MX2022002473 A MX 2022002473A MX 2022002473 A MX2022002473 A MX 2022002473A MX 2022002473 A MX2022002473 A MX 2022002473A MX 2022002473 A MX2022002473 A MX 2022002473A
Authority
MX
Mexico
Prior art keywords
engineered
lipase polypeptides
engineered lipase
lipase variants
compositions
Prior art date
Application number
MX2022002473A
Other languages
English (en)
Inventor
Nikki Dellas
Judy Victoria Antonio Viduya
Stephanie Sue Galanie
William Casey Hallows
Kristen Jean Vallieu
Chinping Chng
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of MX2022002473A publication Critical patent/MX2022002473A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona polipéptidos de lipasa modificados genéticamente y composiciones de los mismos; los polipéptidos de lipasa diseñados genéticamente se han optimizado para proporcionar termoestabilidad, estabilidad de proteasa y estabilidad mejoradas en una variedad de condiciones de pH, incluidas condiciones ácidas (pH <7) y básicas (Ph >7); la invención también se refiere al uso de las composiciones que comprenden los polipéptidos de lipasa diseñados genéticamente con fines terapéuticos y nutricionales; la presente invención también proporciona polinucleótidos que codifican los polipéptidos de lipasa diseñados genéticamente, así como los métodos para producir los polinucleótidos y polipéptidos de lipasa diseñados genéticamente.
MX2022002473A 2019-08-30 2020-08-28 Variantes de lipasa modificadas geneticamente. MX2022002473A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962894019P 2019-08-30 2019-08-30
PCT/US2020/048405 WO2021041809A1 (en) 2019-08-30 2020-08-28 Engineered lipase variants

Publications (1)

Publication Number Publication Date
MX2022002473A true MX2022002473A (es) 2022-08-02

Family

ID=74680918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002473A MX2022002473A (es) 2019-08-30 2020-08-28 Variantes de lipasa modificadas geneticamente.

Country Status (11)

Country Link
US (1) US11987823B2 (es)
EP (1) EP4022049A4 (es)
JP (1) JP2022545718A (es)
KR (1) KR20220106738A (es)
CN (1) CN115175995A (es)
AU (1) AU2020336468A1 (es)
BR (1) BR112022003705A2 (es)
CA (1) CA3152763A1 (es)
IL (1) IL290978A (es)
MX (1) MX2022002473A (es)
WO (1) WO2021041809A1 (es)

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
WO1996000787A1 (en) 1994-06-30 1996-01-11 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1998031816A1 (en) 1997-01-17 1998-07-23 Regents Of The University Of Minnesota Dna molecules and protein displaying improved triazine compound degrading ability
AU743305C (en) 1997-01-17 2006-03-30 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
JP3712255B2 (ja) 1997-12-08 2005-11-02 カリフォルニア・インスティチュート・オブ・テクノロジー ポリヌクレオチドおよびポリペプチド配列を生成するための方法
JP2002510506A (ja) 1998-04-02 2002-04-09 テラス ジェネティック リソーシズ，インコーポレイティド 遺伝子配列に遺伝障害を有する植物を得る方法
AU747190B2 (en) 1998-05-01 2002-05-09 Maxygen, Inc. "Optimization of pest resistance genes using DNA shuffling"
JP2002517995A (ja) 1998-06-17 2002-06-25 マキシジェン， インコーポレイテッド 所望の特性を有するポリヌクレオチドを生成するための方法
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
AU5347999A (en) 1998-08-12 2000-03-06 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
CA2345203A1 (en) 1998-10-07 2000-04-13 Maxygen Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
EP1129184A1 (en) 1998-11-10 2001-09-05 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
ES2341217T3 (es) 1999-01-19 2010-06-17 Maxygen, Inc. Recombinacion de acidos nucleicos mediada por oligonucleotidos.
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
US6365377B1 (en) 1999-03-05 2002-04-02 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
IL150291A0 (en) 2000-01-11 2002-12-01 Maxygen Inc Integrated systems and methods for diversity generation and screening
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
WO2001075767A2 (en) 2000-03-30 2001-10-11 Maxygen, Inc. In silico cross-over site selection
DE60144145D1 (de) 2000-04-03 2011-04-14 Maxygen Inc Subtilisin-variante
US6858422B2 (en) * 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
EP2278509B1 (en) 2002-03-01 2014-11-19 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional biomolecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US7620500B2 (en) 2002-03-09 2009-11-17 Maxygen, Inc. Optimization of crossover points for directed evolution
JP4588695B2 (ja) * 2003-01-30 2010-12-01 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ リパーゼの安定的な変異体
CA2889013C (en) 2003-03-07 2018-07-17 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US7629157B2 (en) 2003-08-11 2009-12-08 Codexis, Inc. Ketoreductase polypeptides and related polynucleotides
PL2198880T3 (pl) 2004-10-14 2017-04-28 Eli Lilly And Co. Kompozycje zawierające lipazę, proteazę i amylazę do leczenia niewydolności trzustki
WO2006099207A2 (en) 2005-03-10 2006-09-21 Diversa Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
EP2035556B1 (fr) 2006-06-15 2015-07-29 Laboratoires Mayoly Spindler Procede de production de lipase, cellule de yarrowia lipolytica transformee apte a produire ladite lipase et leurs applications
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP2250595B1 (en) 2008-02-12 2017-06-14 Codexis, Inc. Method of selecting an optimized diverse population of variants
EP2250594B1 (en) 2008-02-12 2017-04-19 Codexis, Inc. Method of generating an optimized, diverse population of variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
CN102066561B (zh) 2008-06-13 2013-09-25 科德克希思公司 合成多核苷酸变体的方法
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
JP5970189B2 (ja) 2009-01-29 2016-08-17 ノルドマルク・アルツナイミッテル・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト 医薬調製物
WO2013003290A1 (en) 2011-06-28 2013-01-03 Codexis, Inc. Protein variant generation by region shuffling
HUE039516T2 (hu) 2010-02-04 2019-01-28 Biomarin Pharm Inc Eljárás prokarióta fenilalanin-liáz variánsok tisztítására
MY171837A (en) * 2010-09-14 2019-11-01 Univ Putra Malaysia Novel microorganisms producing thermostable lipase from oil contaminated sample and methods thereof
WO2013159055A1 (en) 2012-04-20 2013-10-24 Codexis, Inc. Production of fatty alcohols from engineered microorganisms
CN104428313B (zh) 2012-05-11 2017-11-17 科德克希思公司 工程化亚胺还原酶以及用于酮和胺化合物的还原胺化的方法
US9879239B2 (en) * 2012-09-14 2018-01-30 REG Life Sciences, LLC Enzyme variants with improved ester synthase properties
JP6377078B2 (ja) 2013-01-31 2018-08-22 コデクシス， インコーポレイテッド 相互作用する構成要素を有する生体分子を同定するための方法、システム、およびソフトウェア
AU2015370125B2 (en) 2014-12-22 2022-02-03 Codexis, Inc. Human alpha-galactosidase variants
DE102015114859A1 (de) 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Verwendung einer pharmazeutischen Zusammensetzung, enthaltend mindestens ein Verdauungsenzym, bei der künstlichen Ernährung
CA3066767A1 (en) 2017-06-30 2019-01-03 Codexis, Inc. T7 rna polymerase variants
WO2019185612A1 (en) 2018-03-26 2019-10-03 Basf Se Method of reducing soil water repellency

Also Published As

Publication number Publication date
US20210062168A1 (en) 2021-03-04
EP4022049A4 (en) 2023-11-01
JP2022545718A (ja) 2022-10-28
EP4022049A1 (en) 2022-07-06
IL290978A (en) 2022-05-01
KR20220106738A (ko) 2022-07-29
AU2020336468A1 (en) 2022-03-03
WO2021041809A1 (en) 2021-03-04
US11987823B2 (en) 2024-05-21
CA3152763A1 (en) 2021-03-04
BR112022003705A2 (pt) 2022-05-24
CN115175995A (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
WO2017191274A3 (en) Rna encoding a therapeutic protein
EP2493507A4 (en) ANTAGONISTS AND VARIANTS AX213 AND AX132 PCSK9
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
PH12018501355A1 (en) Rsv f protein mutants
MX2023010757A (es) Variantes de proteasa y sus usos.
CA2783820C (en) Protease variants
WO2004033659A3 (en) Novel tumor suppressor gene and compositions and methods for making and using the same
TNSN08024A1 (en) 7-substituted aza-indazoles, compositions containing same, production method and use thereof
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
WO2008057459A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008057458A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
MY161415A (en) A homeopathic formulation
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MX2021000322A (es) Enzimas de variante fosfopentomutasa modificada geneticamente.
MX2021010264A (es) Formulaciones estables de proteina.
MX2021000328A (es) Enzimas de variantes de galactosa oxidasa modificadas geneticamente.
PH12021551372A1 (en) Human alpha-galactosidase variants
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
MX2021015761A (es) Polipeptidos.
MX2021000323A (es) Enzimas de variante de pantotenato quinasa modificadas geneticamente.
MX2020002964A (es) Variantes de lipasa y composiciones de microcapsula que comprenden las variantes de lipasa.
MX2022001641A (es) Composiciones fermentadas y procedimientos de preparacion de las mismas.
MX2023002421A (es) Variantes de amilasa modificadas geneticamente.